Navigation Links
Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
Date:4/27/2012

CHICAGO, April 27, 2012 /PRNewswire/ -- Today, Zacks Equity Research discusses the Pharmaceuticals & Biotech Industry, including Eli Lilly (NYSE: LLY), Forest Labs (NYSE: FRX), ViroPharma (Nasdaq: VPHM), Novartis (NYSE: NVS) and United Therapeutics (Nasdaq: UTHR).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

A synopsis of today's Industry Outlook is presented below. The full article can be read at  http://www.zacks.com/stock/news/73859/pharma-biotech-stock-outlook-april-2012

We recommend avoiding names that offer little growth or opportunity for a take-out. These include companies which are developing drugs that are likely to face regulatory hurdles. The FDA has been exercising more caution in granting approval to new products and several candidates are facing delays in receiving final approval.

We would also avoid companies like Eli Lilly (NYSE: LLY), which are facing patent expirations on key products and whose new products may not be enough to make up for the loss of revenues that will take place once generics enter the market. 2012 will be a challenging year for Eli Lilly, with the company losing patent exclusivity on Zyprexa in October 2011. Zyprexa sales should erode rapidly with the entry of generics. Moreover, we expect continued erosion of Gemzar sales due to genericization. Another company that is highly exposed to a patent cliff is Forest Labs (NYSE: FRX).

Another company facing generic competition is ViroPharma (Nasdaq: VPHM). Estimates are down significantly as the company's lead product, Vancocin, began facing generic competition recently. The entry of generic versions will lead to a rapid decline in branded Vancocin sales. We expect ViroPharma to remain under pressure as generic players launch their versions of the drug.

We currently have a Zacks #4 Rank on Novartis (NYSE: NVS). We expect 2012 to be a challenging year for the company given manufacturing issues, pricing headwinds, generic competition and unfavorable currency movement. The company's first quarter 2012 results were below expectations.

United Therapeutics (Nasdaq: UTHR) also carries a Zacks #4 Rank. We are not too bullish on the company's chances of gaining US approval for oral treprostinil, given the mixed data on the candidate. Moreover, the company's weak late-stage pipeline concerns us.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2679.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4581.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter:  http://twitter.com/zacksresearch

Join us on Facebook:  http://www.facebook.com/ZacksInvestmentResearch

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

 

 

 


'/>"/>
SOURCE Zacks Investment Research, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Leslie Zacks Joins Arbor Pharmaceuticals as General Counsel and Chief Compliance Officer
2. Zacks Voice of the People highlights opportunities with Walgreen, Occidental Petroleum and Brown & Brown
3. The Zacks Analyst Blog Highlights: UnitedHealth Group, Aetna, WellPoint, CIGNA and Wright Medical Group
4. Zacks Releases Four Powerful Buy Stocks: Chemtura, Cardinal Health, HiTech Pharmacal and Gardner Denver
5. Zacks Industry Outlook Highlights: Vertex Pharma, Human Genome Sciences, Biogen Idec and Perrigo
6. The Zacks Analyst Blog Highlights: Pfizer, Bristol - Myers Squibb, Eli Lilly, Forest Laboratories and Abbott Laboratories
7. Zacks Industry Outlook Highlights: Vertex Pharma, AstraZeneca, Abbott Labs, Allergan and Onyx Pharmaceuticals
8. Zacks Investment Research Initiates Coverage on Viral Genetics
9. Zacks Rates CardioGenics Outperform With Six-Month Target of $1.22
10. Advance Recruitment Delighted With Positive Outlook for Medical Device Sales Industry
11. Industry Leading Pharmaceutical News Website in-Pharmatechnologist.com Refocused and Relaunched
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2020)... PLEASANTON, Calif. (PRWEB) , ... May 21, 2020 ... ... (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced ... as a UroLift® Center of Excellence. The designation recognizes that Dr. Divakaruni has ...
(Date:5/16/2020)... HARRISBURG, Pa. (PRWEB) , ... ... ... are licensed allied healthcare professionals, who in collaboration with a physician, can ... care, examination and clinical diagnosis, therapeutic intervention, and rehabilitation of injuries and ...
(Date:5/15/2020)... ... May 15, 2020 , ... AppleGate Recovery, ... Recovery Centers (MARC), an office-based opioid treatment (OBOT) program with two locations near ... (MAT) and recovery services in a physician’s office setting. , AppleGate Recovery ...
Breaking Medicine Technology:
(Date:5/21/2020)... ... May 21, 2020 , ... ... Clinical Research, CenterWatch eLearning , https://www.centerwatch.com/products/category/2764-elearning/product/472-the-crc-trainer , Wherever one falls ... Companion to the CRC’s Guide to Coordinating Clinical Research provides the perfect ...
(Date:5/21/2020)... , ... May 21, 2020 , ... ... years of experience of GSCG, VITA NOVAS has already gained ground with the ... , vitamins and stimulating biological products intravenously, guaranteeing an effective way for the ...
(Date:5/21/2020)... , ... May 21, 2020 , ... ESO , ... hospitals, today announced the findings of its 2020 ESO Fire Service Index . ... EMS calls versus fire-related calls, first apparatus turnout time and travel time, the most ...
(Date:5/21/2020)... ... ... JNL Technologies Inc. , a manufacturer of safety and security products for ... software. This tool allows companies to create an electronic screening record of anyone entering ... management. , SafeHealth allows you to create a custom set of screening questions, allowing ...
(Date:5/16/2020)... (PRWEB) , ... May 15, 2020 , ... ... announced a new collaboration with the Open Source Medical Supplies (OSMS). The organization ... of their efforts to reduce the spread of COVID-19. , Created as a ...
Breaking Medicine News(10 mins):